Zydus Lifesciences has informed that it enclosed a copy of press release dated December 6, 2023 titled ‘Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics’.
The above information is a part of company’s filings submitted to BSE.